Skip to content
Peptigraph home
Shop Peptides50% off*

Can retatrutide cause high blood pressure?

Pooled randomised trials found the opposite of a rise: retatrutide lowered systolic blood pressure by 6.79 mmHg and diastolic by 2.46 mmHg on average.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Pooled randomised trials found the opposite of a rise: retatrutide lowered systolic blood pressure by 6.79 mmHg and diastolic by 2.46 mmHg on average.[1]

A separate pooled analysis reported a fall of 9.88 mm Hg systolic and 3.88 mm Hg diastolic.[2]

What does rise

The phase 2 obesity abstract reports heart-rate increases that grew with dose and declined after week 24; blood pressure is not named there.[3]

A meta-analysis of weight-loss injections in people without diabetes found retatrutide was associated with a mean heart-rate increase of 3.46 beats per minute over placebo.[4]

Hypertension as a recorded event

In the phase 2 obesity registry, hypertension was recorded for 2 of 70 placebo participants and 4 of 62 in the top-dose step-up arm, small counts without a clear dose pattern.[5]

EG000 is how the phase 2 obesity registry record labels placebo.[5]

EG006 is the obesity phase 2 arm that began at 2 mg and ended at 12 mg.[5]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?Can you drink alcohol while on retatrutide?

More on Retatrutide

Side effectsWhat labels and studies report, and what is unknown.Retatrutide overview

Sources

  1. 1Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026PMID 42371360Accessed 2 Oct 2026
  2. 2Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.Proceedings (Baylor University. Medical Center) · 2025PMID 40291085Accessed 2 Oct 2026
  3. 3Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
  4. 4Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.European journal of medical research · 2026PMID 41582189Accessed 2 Oct 2026
  5. 5A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.